头孢哌酮舒巴坦钠在院内感染应用中的成本效益分析
Cost-effectiveness analysis of cefoperazone sulbactam sodium in nosocomial infection
宋月兰 1王建兵 1刘丽萍1
作者信息
- 1. 山西省晋城市第二人民医院 医院感染管理科,山西 晋城 048000
- 折叠
摘要
目的 探讨头孢哌酮舒巴坦钠在院内(下呼吸道)感染应用中的成本效益.方法 将2014年1月～2017年1月晋城市第二人民医院(神经内科、神经外科)院内感染患者80例作为研究对象进行分组治疗:观察组用头孢哌酮舒巴坦钠治疗,对照组用头孢地嗪钠治疗.详细记录2组患者各项实验数据,并将所获相关数据作统计学分析,探讨头孢哌酮舒巴坦钠在院内感染应用中的成本效益.结果 2组患者临床治疗效果比较,差异无统计学意义;观察组(头孢哌酮舒巴坦钠)成本低于对照组(头孢地嗪钠),差异有统计学意义(P＜0.05).结论 院内感染患者选择头孢哌酮舒巴坦钠治疗,其临床疗效确切、成本效益高,值得临床上广泛应用.
Abstract
Objective To investigate the cost-effectiveness of cefoperazone sulbactam sodium in treating nosocomial infection (lower respiratory tract infection).Methods 80 cases of nosocomial infection in Jincheng Second People's Hospital from January 2014 to January 2017 were treated as the subjects: the observation group was treated with cefoperazone sulbactam sodium and the control group was treated with cefodizime sodium.The data of two groups of patients were recorded and the data were analyzed statistically.The cost-effectiveness of cefoperazone sulbactam sodium in hospital infection was discussed.Results There was no significant difference in the clinical curative effect between the two groups.The cost of observation group (cefoperazone sulbactam sodium) was lower than that of the control group (cefodizime sodium), the difference was statistically significant (P< 0.05).Conclusion Patients with nosocomial infection choose to use cefoperazone sulbactam sodium as the treatment method, which has exact clinical efficacy, high cost-effectiveness.It is worthy of clinical wide application.
关键词
头孢哌酮舒巴坦钠/院内感染/成本效益Key words
Cefoperazone sulbactam sodium/nosocomial infection/cost-effectiveness引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据